MedTrace Logo

Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries

NCT02278991 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 149

Last updated 2019-10-09

No results posted yet for this study

Summary

Objective of this study is to evaluate the safety and efficacy of Lutonix 035 Drug Coated Dilatation PTA Catheter with Bard LifeStent Vascular Stent (hereinafter referred to as LifeStent) for treatment of long (10-24 cm) lesions in the SFA and/or proximal popliteal artery.

Conditions

Interventions

DEVICE

Lutonix Drug Coated Balloon

Subject will receive treatment with the Lutonix Drug Coated Balloon

Sponsors & Collaborators

  • C. R. Bard

    lead INDUSTRY

Principal Investigators

  • Thomas Zeller, Prof.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-09-30
Completion
2018-10-02

Countries

  • Germany
  • Greece
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02278991 on ClinicalTrials.gov